

Addressing high drug prices: What can be learned from European policies?

Ensuring access to medicines How to redesign pricing, reimbursement and procurement? Policy Brief No. 30 of the European Observatory on Health Systems and Policies

Sabine Vogler

Webinar of the Knowledge Network for Innovation and Access to Medicines,
A project of the Global Health Centre, Graduate Institute of Geneva

13 December 2018


Outline



Introduction

- » High prices challenge the
 - » affordability of new medicines &
 - » financial sustainability
- » Increases in pharmaceutical expenditure
 - » particularly in hospitals (lack of data)
- » Concerns about
 - » high prices and
 - » limited or additional therapeutic benefits

Annual growth rate of retail pharmaceutical expenditure 2011–2016



Note: VHI: voluntary health insurance; OOP: Out-of-pocket expenditures; United Kingdom 2013–2016; Bulgaria 2012–2016. There are breaks in the series for Czech Republic, Italy and Slovakia. Countries are listed according to the annual growth rate of total retail pharmaceutical expenditures.

Introduction

- » Affordability and sustainability concerns have been on the agenda of previous EU Presidencies

C 438/12 EN Official Journal of the European Union 6.12.2014

Council conclusions on innovation for the benefit of patients
(2014/C 438/06)

30.6.2017 EN Official Journal of the European Union C 206/3


Council conclusions on Encouraging Member States-driven Voluntary Cooperation between Health Systems
(2017/C 206/02)



PRESS RELEASE
350/16
17/06/2016

Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States

- » Policy brief(s) in support of the Austrian Presidency



Policy briefs on ensuring access to medicines under the auspices of the Austrian Presidency

e 20
u 18

e 20
u 18


Triple aim

- Ensuring **access**: making sure that patients have timely and affordable access to safe and effective medicines;
- Stimulating **innovation**: providing incentives for research that will lead to innovative medicines that effectively target real therapeutic needs;
- Safeguarding **sustainability**: developing the mechanisms to purchase these medicines at affordable prices in order to protect the sustainability of pharmaceutical budgets.

- a t

- a t

How the policy briefs fit together



Act or process
of determining a price
(price-setting practices
in the context of price
regulation)

Covering the cost
of HC services by a
third-party payer

Process of purchasing
goods, works or services
(e.g. medicines) through
a formal process
(e.g. tender)

- » How can pharmaceutical pricing, reimbursement and procurement be redesigned to ensure affordable and sustainable patient access to new medicines?
 - » Which policies for pricing, reimbursement and procurement of new medicines are **currently** in place in EU Member States? What are their **strengths** and **limitations**?
 - » Which **alternative approaches** to these policies might help improve affordable and sustainable patient access to new medicines? Are they **feasible**?
 - » How could increased **transparency** on prices and **cooperation** between EU Member States provide a contribution to more affordable and sustainable patient access to new medicines?



Results – Frequently used PRP policies for new medicines

Policy	Definition	Use in EU MS	Benefits	Limitations
External price referencing (EPR)	Practice of using price(s) of a medicine in other countries	26 of 28 EU MS, IS, NO and CH Usually accompanied by other pricing policies Differences in methodology	Evidence for cost-containment (savings), particularly in the short run Methodology strongly impacts the results	Availability concerns (“strategic launches”) Reference to list prices (overpaying, information asymmetry)
Managed entry agreements (MEA)	Agreement between manufacturer and payer to enable access to a medicine	Increasingly used for high-priced medicines (oncology, OMP) Mainly financial-based MEAs (no complete picture of use)	Facilitate access to medicines otherwise unaffordable Outcome-based MEAs could enable collection of RWD	Confidentiality of prices and clinical data → weakening of negotiation power MAH requests higher initial prices High transaction costs & administrative efforts



Results – Tools to support decision-making

Policy	Definition	Use in EU MS	Benefits	Limitations
Health Technology Assessment (HTA)	Multidisciplinary process that summarises info. about medical, social, ec. & ethical issues of HT to inform policy-makers	Use varies between MS (e.g. one government agency, more than 1 HTA agency) EUnetHTA	Provides robust data to inform PR decisions	Technical tool that cannot, in isolation, make decisions
Horizon scanning	Systematic identification of HT that are new & have the potential to affect health, health services and/or society	Traditionally done by research institutions, HS systems being built up	Supportive tool for budget impact preparedness → supports prioritization process for allocation of funds	Establishment and maintenance is extremely time-intensive and costly Limitations of (public) information



Results – Selected funding models for new medicines

Policy	Definition	Use in EU MS	Benefits	Limitations
Amortization	Mechanism for paying for a large upfront cost by making smaller payments over time	–	Allows payers to fund expensive therapies while balancing the budgets within a year	Might postpone sustainability issues No evidence on ability to improve affordability
Specific funds	Alternatives to established rules and enable R for defined medicines	In some MS E.g. Cancer Drug Fund (England), funds for innovation (Italy)	Improve to medicines otherwise non-funded	Risk of funding medicines that are not cost-effective Incentive for MAH to charge higher prices Funds tended to increase over time



Results – Selected funding models for new medicines

Policy	Definition	Use in EU MS	Benefits	Limitations
Tendering	Procurement approach based on a formal and competitive procedure	In the hospital sector for some high-priced medicines Increased collaboration between hospitals, shift to regional and national levels	Substantial savings	“Race to the bottom” → too low prices?, availability issues
Measures to increase uptake of biosimilar medicines	Measures targeted at prescribers, pharmacists	Switching at prescribers level is supported in several MS. Substitution of biosimilar medicines at pharmacy level not widely used	Savings	–

Results – Barriers & limitations for PRP in the existing framework

- » Intransparency of prices and further (R+D costs)
 - » Payers have to trust the promise of getting “the best deal”
 - » Unavailability of “real prices” → negative impact on EPR
 - » Weakening of the bargaining power
 - » Industry argument of return for investment of R+D cost

- » Imbalances in negotiation power
 - » Linked to the intransparency
 - » Local payers/authorities meet global market players
 - » Staffing level of authorities low (additional pressure due to financial crisis)
 - » Capacity and qualification

Results – Barriers & limitations for PRP in the existing framework

- » Fragmentation of the pharmaceutical sector
 - » Small markets (not attractive for industry)
 - » Fragmentation between out-patient and in-patient sectors
 - » Little contact between authorities along the life-cycle

- » Legal and organisational barriers
 - » E.g. tendering only allowed under certain conditions
 - » Parallel trade
 - » ...

Solutions




Solutions


Pharmaceutical
life-cycle

Collaborative
approaches

Methodological
advances



Solutions



Conclusions

- » How can pharmaceutical pricing, reimbursement and procurement be redesigned to ensure affordable and sustainable patient access to new medicines?
 - » Which policies for pricing, reimbursement and procurement of new medicines are **currently** in place in EU Member States? What are their **strengths** and **limitations**?
 - » Which **alternative approaches** to these policies might help improve affordable and sustainable patient access to new medicines? Are they **feasible**?
 - » How could increased **transparency** on prices and **cooperation** between EU Member States provide a contribution to more affordable and sustainable patient access to new medicines?
- » EU MS use a range of PRP policies
- » Variation in use and in methodologies
- » Each policy has strengths and limitations
- » Limitations of existing policies have become increasingly clear
- » Alternative approaches range
 - » from policy options with high feasibility, building on existing measures to
 - » options expanding on existing experience and introducing new elements
- » Collaborative approaches have been proposed as a way forward
- » Measures to overcome information asymmetry and fragmentation and to strengthen the bargaining power of payers appear key
- » Limited evidence on new initiatives → need for systematic evaluations

Thank you for your attention!

Dr. Sabine Vogler

Stubenring 6


1010 Vienna, Austria

T: +43 1 515 61-147

F: +43 1 513 84 72

E: sabine.vogler@goeg.at

www.goeg.at whocc.goeg.at



http://www.euro.who.int/_data/assets/pdf_file/0009/379710/PolicyBrief_AUSTRIA_PB30_web_13082018.pdf